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A B S T R A C T
Background and purpose: Attention-deﬁcit/hyperactivity disorder (ADHD) is one of the most common health
disorders among children. Some patients do not respond to methylphenidate or cannot tolerate its side eﬀects.
Sweet almond syrup as a Persian Medicine preparation has been used for many years. This study aims to evaluate
the eﬃcacy and safety of sweet almond for ADHD children.
Materials and methods: Fifty children aged 6-14 years with ADHD were recruited to the study. The participants
were randomly assigned to two groups to receive either methylphenidate or sweet almond syrup. The outcomes
were assessed using the Parent and Teacher ADHD Rating Scale every two weeks for 8 weeks.
Results: Results showed that the two treatments had similar eﬀects on symptom reduction in ADHD children. No
signiﬁcant diﬀerences were observed between the two groups (F=2.3, df=1, p=0.13, F=0.57, df=1, p=0.47).
Conclusion: Sweet almond may be an eﬀective treatment for ADHD children.
1. Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is the most pre-
valent neurodevelopmental behavioral disorder in children with in-
creasing incidence rate [1]. The global prevalence of ADHD is highly
heterogeneous, yet is estimated at 5.29% in some studies. It is usually
more common in boys than girls [2]. Although the etiology of ADHD is
not completely understood, imbalance in dopaminergic and nora-
drenergic neurotransmission is one of the main causes [3]. This disorder
is characterized by various symptoms of inattention, hyperactivity, and
impulsivity according to the Diagnostic and Statistical Manual of
Mental Disorders, 5th edition (DSM-5) [4].
Psychostimulant medications such as methylphenidate (MPH) and
amphetamines play an important role in the treatment of ADHD [5].
However, up to 30% of all children with ADHD do not respond to
medications or suﬀer from medication-related adverse eﬀects such as
reduced appetite, mood changes, and sleep disturbances [6]. Therefore,
there is a need to ﬁnd alternative methods to relieve the symptoms of
ADHD while these medication-related side eﬀects are avoided.
Complementary and alternative medicine (CAM) is deﬁned as “a
group of diverse medical and health care systems, practices, and pro-
ducts that are not presently considered to be part of conventional
medicine” [7]. Although various studies have documented the use of
CAM among children and adolescents, most have lacked the scientiﬁc
rigor to establish clear beneﬁts. The most common types of CAM are
herbal/dietary supplements, acupuncture, massage, chiropractic, and
homeopathy. Meanwhile, the most commonly studied diseases and
symptoms in children treated with CAM are pain, headache, ADHD,
asthma, and colic [8].
CAM is appealing to parents who like more natural interventions for
their children, so approximately 50% of parents of children with ADHD
use CAM alone or in combination with other drugs or substances [9].
Persian Medicine (PM), as one of the complementary medicine schools,
provides diﬀerent strategies to prevent and treat diseases in various life
stages such as childhood.
Nuts and their oil have been widely used in traditional medicine for
the treatment of a variety of illnesses. For instance, Iranian people knew
sweet almond (fruits of Prunus amygdalus var. dulcis) and its nutritional
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values from the past and used it in their diet. Masters of PM have be-
lieved that sweet almond has some medicinal properties, in addition to
nutritional values, which can promote health and/or prevent diseases.
Accordingly, they considered it as a functional food [10]. Functional
foods are thought to provide positive eﬀects on speciﬁc body functions
and prevent or mitigate diseases. These foods support child develop-
ment for the prevention and treatment of diseases and for enhancing
neurodevelopmental potentials [11].
Regular use of sweet almond has such beneﬁcial eﬀects as neuro-
protective activities [12], antidiabetic eﬀect [13,14], reduced risk of
cardiovascular diseases [15], as well as increased HDL cholesterol and
decreased LDL cholesterol levels [16]. Furthermore, its im-
munostimulant activity [17] along with antioxidant and antiradical
eﬀects have also been recognized [18]. Sweet almond is an eﬀective
and healthy food for both mind and body [19]. Animal studies have
suggested that sweet almond can improve memory and learning
[12,20]. It has also stress-relieving and anxiolytic eﬀects like those of
diazepam [19].
Based on the principles of PM, it was hypothesized that
sweet almond would be useful for the treatment of ADHD in children.
The aim of this study was to evaluate the eﬃcacy and safety of
sweet almond compared with the standard treatment through a ran-
domized controlled trial.
2. Materials and methods
2.1. Trial setting and design
This randomized, triple-blind, single-center clinical trial was con-
ducted between November 2015 and February 2017 in Ziaeian
Hospital, Tehran, Iran. The trial was registered in Iranian Registry of
Clinical Trials with the registration number: IRCT2015050922165N1. It
was also approved by the Ethics Committee of Research Center at
Tehran University of Medical Sciences in accordance with the
Declaration of Helsinki (IR.TUMS.REC.1394.195). The study design and
aims were explained to both children and their parents or guardians
and written informed consent was obtained from the patients’ parents
or guardians.
2.2. Participants
The participants were 50 outpatient children (33 boys and 17 girls)
aged between 6 and 14 years who clearly met the DSM-5 diagnostic
criteria for ADHD [4], and who were recruited from outpatient child
clinic of Ziaeian Hospital. A child and adolescent psychiatrist conﬁrmed
the diagnosis of ADHD before the participants were recruited into the
study. All patients had been newly diagnosed with mild to moderate
ADHD of combined subtype according to the DSM-5. They should have
not taken any non-pharmacological treatment, other psychotropic
medications, or CAM during the study.
Children were excluded from the study if they had signiﬁcant
chronic medical conditions such as cardiovascular diseases, gastro-
intestinal disorders, seizures, and organic brain disorders, and if they
were clinically current drug abusers or dependent on drugs within the
last 6 months. In addition, patients were excluded if they had any de-
velopmental disorders, other psychiatric disorders or intellectual dis-
abilities (intelligence quotient< 70). The children should not have had
a history of allergy to sweet almond and its products. If severe side
eﬀects and drug intolerance occurred during the study and parents or
patients were not satisﬁed with the treatment, they would be excluded
from the sample. The participants underwent a standard clinical as-
sessment comprising a medical history, a psychiatric evaluation, and a
structured diagnostic interview.
2.3. Interventions
The patients included in the study were randomized in a 1:1 ratio
using a computer-generated code to receive either sweet almond syrup
or methylphenidate (Ritalin®, Novartis, Switzerland). Fifty-nine pa-
tients were randomly assigned using the sealed envelope method to
receive methylphenidate (MPH) at a dose of 1mg/kg/day and a ther-
apeutically ineﬀective syrup 5 cc/day (three times a day) as a placebo
(Group 1) or sweet almond syrup 5 cc/day (three times a day) and a
therapeutically ineﬀective tablet as a placebo (Group 2) during an 8-
week triple-blind, randomized clinical trial. The patients received a 5-
mg tablet (half of MPH or placebo tablet) twice daily in the ﬁrst week,
followed by a 10-mg tablet twice daily. The patients weighing beyond
30 kg received a 10-mg tablet thrice daily from the third week of the
study.
The person who administered the medications, the assessor, and
patients along with their parents were blinded to the allocation of study
groups. Both sweet almond and placebo syrup as well as methylphe-
nidate and placebo tablets were identical in appearance, color, smell
and label. No recommendations were made to alter diet. The partici-
pants were only asked to refrain from consuming sweet almond and
almond products during the study.
2.4. Drug preparation
Methylphenidate tablets (10mg) were procured from the Novartis
Pharmaceutical Company, Switzerland. The placebo tablets were also
made by the Iranian Institute of Medicinal Plants. The sweet almond
syrup was prepared based on the principles of PM by adding almond
extract to simple syrup [10]. The placebo syrup was prepared based on
the simple syrup formula of the British Pharmacopoeia [21] including
approved color additives (magnolia Co. E−150a). Both syrups were
made in the Traditional Pharmacy Department of the School of Tradi-
tional Medicine and supplied in 125-mL bottles, containing either
sweet almond syrup or placebo. Laboratory tests were performed for
diﬀerent microorganisms, which lied within the normal range.
2.5. Standardization of syrup
The sweet almond syrup was standardized based on essential oils
content. The oil of the sample was extracted according to the procedure
recommended by Folch et al. [22]. The extent of the moisture obtained
from the drying method was about 20.7%. In addition, the Soxhlet
method evaluated the total fat content as about 6.3% of dry matter. The
fatty acid proﬁle determined by gas chromatography analysis was in
good agreement with the value previously reported for almond [23].
The major monounsaturated fatty acid content was oleic acid (C18:1),
while the amount of palmitoleic acid (C16:1) was negligible. The li-
noleic acid (C18:2) was the only polyunsaturated fatty acid present in
the sample. The main saturated fatty acids were palmitic acid (C16) and
stearic acid (C18).
2.6. Outcome measurement
The main outcome was measured using the Parent and Teacher
ADHD Rating Scale, which is a valid measurement of attention and
behavioral abnormalities. The ADHD Rating Scale has been used ex-
tensively in school-age children in Iran [24–27]. This 18-item scale that
rates ADHD symptoms using a 4-point Likert-type scale is based on the
DSM-5 criteria for ADHD. A score of at least 20 was required for entry
into the study. The treatment outcomes were assessed with the use of
the ADHD Rating Scale at baseline and 14, 28, 42, and 56 days after
intervention. In order to monitor any possible side eﬀects, the Common
Terminology Criteria for Adverse Events (CTCAE, v4.03, 2010) was
applied in all follow-up visits.
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2.7. Statistical analysis
In order to check similarity of the two groups, the Chi-square and
Fisher's exact tests were used for categorical variables, and the in-
dependent t-test was performed for continuous variables. The eﬃcacy
of the administered drugs between and within groups was compared by
using a two-way repeated measures analysis of variance (rANOVA) as
the main analysis. The homogeneity was checked by means of the Box's
M. The Mauchly's sphericity test was also used to test for the condition
of sphericity. In addition, the main side eﬀects and the withdrawal rate
of the study groups were compared using the Chi-square and Fisher's
exact tests. The two groups were considered as a between-subjects
factor (group) and the ﬁve measurements during the treatment were
taken as the within-subjects factor (time). The results are presented as
mean ± standard deviation (SD). The signiﬁcance levels were set at
p < 0.05.
The sample size was calculated to be 15 patients in each group on
the basis of following assumptions: a mean diﬀerence (MD) of 5 on the
Teacher and Parent ADHD Rating Scale, study power of 0.8, and a two-
tailed signiﬁcance level of 0.05 according to the ﬁnal diﬀerences be-
tween the two groups. To account for possible attrition of up to 10%, 50
patients were recruited to the study (25 patients per group).
3. Results
3.1. Participants
Out of the 96 patients who were referred to the hospital, 59 patients
entered the trial and were randomized to receive either MPH (n= 29)
or sweet almond syrup (n=30). Excluded from the ﬁnal analysis, nine
patients withdrew from the study before the ﬁrst follow-up visit due to
parents’ lack of collaboration. Further details are shown in the
CONSORT (Consolidated Standards of Reporting Trials) ﬂow diagram
(Fig. 1).
No signiﬁcant diﬀerence was found between the two groups for such
certain demographic/clinical characteristics as gender. According to
the independent t-test, a signiﬁcant diﬀerence was found between age,
weight, and height (p < 0.05), although these diﬀerences were not
clinically signiﬁcant and did not require to be adjusted in the main
analysis (Table 1). The mean age of the 50 patients included in this
study was 7.1 ± 1.36 years with a male:female ratio of 2:1.
3.2. Outcomes
3.2.1. The parent ADHD Rating Scale
The mean ± SD of the Parent ADHD Rating Scale scores of the two
groups are presented in Fig. 2 (total score) and Table 2 (subscales).
There was no signiﬁcant diﬀerence in the baseline Parent ADHD Rating
Scale scores between the two groups (38.8 ± 8.8 vs 35.6 ± 6.0,
p=0.25). Based on the analysis, the results showed a signiﬁcant
treatment eﬀect over time (F=83.7, df= 4, p < 001). This suggests a
decreased Parent ADHD Rating Scale scores over time for the study
groups.
There was no signiﬁcant diﬀerence between the two groups with
regard to the Parent ADHD Rating Scale scores (F= 2.3, df= 1,
p=0.13). Analytical comparison of the Parent ADHD Rating Scale
scores in hyperactivity and inattention categories (Table 2) indicated no
statistically signiﬁcant diﬀerences between the two groups in any of the
visits (p > 0.05). There was no interaction between the type of drugs
and time variable (F= 1.1, df= 4, p= 0.37). In other words, both
treatment groups exhibited a similar declining trend, which was linear,
in ADHD symptoms over the 8-week period (Fig. 2).
Fig. 1. CONSORT ﬂow diagram of the study participants.
Table 1
Demographic/clinical characteristics of the participants.
Sweet almond group MPH group p-value
Boy, n 16 17
Girl, n 9 8
Age (mean ± SD) 6.6 ± 1.0 7.5 ± 1.5 0.02
Weight (mean ± SD) 23.7 ± 6.6 30 ± 11.6 0.02
Height (mean ± SD) 128.1 ± 7.5 133.7 ± 9.9 0.03
Type of ADHD All combined All combined 1
ADHD, attention-deﬁcit/hyperactivity disorder; MPH, methylphenidate hy-
drochloride; SD, standard deviation.
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3.2.2. The teacher ADHD Rating Scale
The mean ± SD of the Teacher ADHD Rating Scale scores of the
two groups are presented in Fig. 3 (total score) and Table 2 (subscales).
There was no signiﬁcant diﬀerence in the baseline Teacher ADHD
Rating Scale scores between the two groups (35.5 ± 7.9 vs
36.8 ± 8.7, p=0.49). The results, however, showed a signiﬁcant
treatment eﬀect over time (F=74.1, df= 4, p < 0.001). The diﬀer-
ences between the two groups on the Teacher Rating Scale scores were
not signiﬁcant (F= 0.57, df= 1, p=0.47); therefore, the eﬀect of
sweet almond syrup and MPH was similar.
Analytical comparison of the Teacher ADHD Rating Scale scores in
hyperactivity and inattention category (Table 2) showed no statistically
signiﬁcant diﬀerences between the two groups in any of the visits
(p > 0.05). The trend of two treatment groups was similar over time
and the diﬀerence was not signiﬁcant (F= 2.24, df= 2, p=0.06).
3.3. Safety and tolerability
No serious adverse events were observed during the study. All no-
ticed adverse eﬀects were mild to moderate and transient. According to
Table 3, the adverse events were more commonly reported in patients
receiving MPH. Loss of appetite and trouble in sleeping were the most
common side eﬀects in the MPH group. In patients receiving
sweet almond syrup, the most frequently reported adverse event was
increased appetite. The frequency of appetite changes, sadness, and
sleeping late were signiﬁcantly diﬀerent between the sweet almond and
MPH groups (p < 0.05).
4. Discussion
In the last decade, ADHD has been on the rise in children. Although
methylphenidate has been considered as an eﬀective treatment for
ADHD in several studies [28–30], the need for long-term therapy and
side eﬀects are the main problems for these patients. The aim of this
study was to evaluate the eﬃcacy of sweet almond syrup on children
with ADHD. The results suggested that sweet almond and methylphe-
nidate are eﬀective in the treatment of ADHD. No signiﬁcant diﬀerence
was observed between the two drugs at the end of the trial.
There is a lack of studies investigating alternative methods such as
herbal products for the treatment of ADHD. The results of a study by Ko
et al. suggest that Korean red ginseng (KRG) extract compared with
placebo may be an eﬀective and safe alternative treatment for children
with inattention and hyperactivity symptoms. It may have neuropro-
tective and antioxidant eﬀects and elevate dopamine and nor-
epinephrine levels [31]. In another study, Li et al. found that Ningdong
granule, a traditional Chinese medicine preparation, was eﬀective for
children with ADHD compared with methylphenidate. Ningdong
granule can improve the metabolism of dopamine and cause fewer side
Fig. 2. Repeated measures for comparison of the eﬀects of two treatments on the Parent ADHD Rating Scale score during the study period. Values are presented as
mean ± standard deviation. ADHD, attention-deﬁcit/hyperactivity disorder; n. s, non-signiﬁcant.
Table 2
ADHD Rating Scale-IV scores of study participants (inattentive and hyper-
active/impulsive subscales).
Time of measurements Sweet almond group MPH group p-value
Parent ADHD Rating Scale (Hyperactivity), mean ± SD
Baseline 20.8 ± 4.2 19.0 ± 4.8 0.15
Week 2 17.4 ± 5.4 14.2 ± 4.7 0.02
Week 4 15.1 ± 6.0 12.8 ± 5.9 0.16
Week 6 12.7 ± 5.9 10.9 ± 6.3 0.29
Week 8 11.3 ± 5.9 10.8 ± 6.3 0.78
Parent ADHD Rating Scale (Inattention), mean ± SD
Baseline 17.9 ± 4.5 16.± 3.3 0.23
Week 2 15.0 ± 4.8 12.± 4.2 0.10
Week 4 12.0 ± 4.7 11.0 ± 4.5 0.43
Week 6 10.5 ± 4.3 9.1 ± 4.4 0.28
Week 8 9.4 ± 4.7 8.9 ± 4.3 0.71
Teacher ADHD Rating Scale (Hyperactivity), mean ± SD
Baseline 18.4 ± 4.6 18.9 ± 6.2 0.75
Week 2 16.4 ± 5.6 14.5 ± 7.3 0.30
Week 4 13.5 ± 4.8 12.3 ± 7.2 0.49
Week 6 11.9 ± 5.0 11.3 ± 6.7 0.70
Week 8 10.6 ± 5.1 10.8 ± 6.8 0.90
Teacher ADHD Rating Scale (Inattention), mean ± SD
Baseline 17.0 ± 4.2 17.8 ± 4.9 0.54
Week 2 15.6 ± 4.5 13.8 ± 5.3 0.19
Week 4 13.2 ± 4.9 11.5 ± 4.9 0.23
Week 6 12.4 ± 5.6 9.6 ± 5.1 0.07
Week 8 10.3 ± 5.5 9.6 ± 4.9 0.61
ADHD, attention-deﬁcit/hyperactivity disorder; MPH, methylphenidate hydro-
chloride; SD, standard deviation.
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eﬀects [32]. An open-label study showed that the standardized extract
of Bacopa monnieri, an Ayurvedic medicine, produced signiﬁcant im-
provement in ADHD symptoms through its neuroprotective and anti-
oxidant eﬀects as well as dopamine regulation [33]. Shakibaei et al.
suggested Ginkgo biloba as a complementary treatment to methylphe-
nidate in the treatment of ADHD, especially in children who are pri-
marily inattentive. This herb has proven antioxidative activity and
enhances cerebral circulation contributing to its neuroprotective eﬀects
[34]. According to Akhondzadeh et al. Passiﬂora incarnata is as eﬀective
as methylphenidate in the treatment of ADHD [25], which might be due
to its neuroprotective eﬀects and the alteration of serotonergic neuro-
transmission in the brain [35].
To the best of our knowledge, our study is the ﬁrst trial evaluating
the eﬃcacy and safety of sweet almond in patients with ADHD, al-
though sweet almond has been used in a variety of dosage forms and for
several diseases [12–16,18,19]. The deﬁnite mechanism for the eﬀect of
sweet almond on ADHD is not speciﬁed, though it has shown
antioxidant and neuroprotective activities and improved memory re-
tention in rats, possibly by elevating acetylcholine levels in the brain
[12].
Serotonin is considered as one of the neurotransmitters involved in
the regulation of cognitive functions. Its low levels in certain areas of
the brain have been assumed as one of the biochemical etiologies of
ADHD [9]. Some studies have suggested that long-term intake of
sweet almond signiﬁcantly elevates whole brain serotonin levels [20],
so it can be eﬀective in ADHD.
Sweet almond is a rich source of essential amino acids, essential
unsaturated fatty acids, vitamins, minerals, and numerous bioactive
substances [36]. One of the trace elements found in sweet almond is
boron, which has anti-inﬂammatory eﬀects. Diﬀerent studies have in-
dicated that boron plays a role in improving human brain functions,
short-term memory, and cognitive performance [37,38]. Further, dif-
ferent studies have suggested that ADHD and other neurodevelop-
mental disorders are associated with deﬁciencies in essential un-
saturated fatty acids that are necessary for brain development [39].
Moreover, animal studies have shown that a chronic deﬁciency in
omega-3 fatty acids aﬀects dopamine levels and its receptors in the
prefrontal cortex of the brain and reduces the brain functions [40].
Therefore, correcting fatty acids levels with sweet almond as a rich
source of unsaturated fatty acids can improve ADHD symptoms.
Neurobiological studies in patients with ADHD have demonstrated a
lack of connectivity in key brain regions, inhibitory control deﬁcits, and
delayed maturation in multiple brain regions [30]. According to PM
references, sweet almond as a functional food yields beneﬁcial eﬀects
on speciﬁc functions of the brain and is very useful in preserving the
vitality of the brain and reinforcing its functions. Furthermore, it has
neurodevelopmental potential and can help to regulate the brain
functions. Masters of PM have emphasized that sweet almond protects
the brain tissue and improves memory, concentration, and mental
alertness [10].
The safety and lower side eﬀects of sweet almond syrup in com-
parison with MPH can be an important advantage in this study and be a
reason for its prescription for ADHD, alone or as an alternative to the
stimulant medications. Less abuse potential of sweet almond syrup
compared with MPH is another important advantage for this drug. In
Fig. 3. Repeated measures for comparison of the eﬀects of two treatments on the Teacher ADHD Rating Scale score during the study period. Values are presented as
mean ± standard deviation. ADHD, attention-deﬁcit/hyperactivity disorder;n.s, non-signiﬁcant.
Table 3
Frequency of the side eﬀects in the two study groups.
Complication Sweet almond group MPH group p-value
Decreased appetite 1 (4%) 15 (60%) < 0.001
Increased appetite 15 (60%) 1 (4%) < 0.001
Insomnia 2 (8%) 6 (24%) 0.24
Increased sleep 4 (16%) 1 (4%) 0.34
Diﬃculty falling asleep 3 (12%) 9 (36%) 0.04
Abdominal pain 2 (8%) 6 (24%) 0.24
Headache None 2 (8%) 0.49
Impulsiveness 1 (4%) 3 (12%) 0.61
Irritability 1 (4%) 6 (24%) 0.09
Nausea 1 (4%) 1 (4%) 1
Vomiting None None None
Constipation None 1 (4%) 1
Diarrhea None None None
Dry mouth None 1 (4%) 1
Sadness None 6 (24%) 0.02
Tic None 1 (4%) 1
Itching None 1 (4%) 1
MPH, methylphenidate hydrochloride.
M.S. Motaharifard, et al. Complementary Therapies in Clinical Practice 36 (2019) 170–175
174
addition, one important diﬀerence in the two methods of treatment in
this study was that our drug was administered in syrup form whose use
is more convenient for children. These ﬁndings suggest that we can
prescribe sweet almond for a long time for children with ADHD.
The most important limitations of our study were the small number
of participants, lack of a placebo group, use of only a ﬁxed dose of
sweet almond syrup, the short duration of follow-up, and not con-
sidering the recurrence rate after discontinuing the treatment.
5. Conclusion
The results of this study suggest that sweet almond syrup can be an
eﬀective and safe complementary and alternative medication in the
treatment of childhood ADHD. Sweet almond can be used as an eﬀec-
tive treatment for children with ADHD, alone or in combination with
stimulant drugs especially in order to reduce the side eﬀects of such
medications. Nevertheless, our study is relatively small and further
trials with larger sample size, various drug dosages, and longer treat-
ment and follow-up duration are warranted. The mechanisms of action
of sweet almond on symptoms of ADHD are also needed to be in-
vestigated.
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